These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29849166)

  • 61. Objective demonstration of eyelid spasm relief with smartphone and custom software in hemifacial spasm patients.
    Gameiro GR; Yabumoto C; Osaki MH; Monteiro LG; Schor P; Osaki TH
    Int Ophthalmol; 2024 Mar; 44(1):144. PubMed ID: 38498055
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Automated Measurement of Tear Film Dynamics and Lipid Layer Thickness for Assessment of Non-Sjögren Dry Eye Syndrome With Meibomian Gland Dysfunction.
    Ji YW; Lee J; Lee H; Seo KY; Kim EK; Kim TI
    Cornea; 2017 Feb; 36(2):176-182. PubMed ID: 28060064
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Anesthesia with EMLA cream for botulinum A toxin injection into eyelids.
    Söylev MF; Koçak N; Kuvaki B; Ozkan SB; Kir E
    Ophthalmologica; 2002; 216(5):355-8. PubMed ID: 12424403
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm.
    Wirtschafter JD; McLoon LK
    Ophthalmology; 1998 Feb; 105(2):342-6. PubMed ID: 9479297
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of Botulinum toxin A application in neuro-ophtalmologic indications on Schirmers test and tears osmolarity.
    Žiak P; Halička J; Kapitánová K; Mojžiš P
    Cesk Slov Oftalmol; 2019; 75(2):74-77. PubMed ID: 31537075
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia.
    Bladen JC; Feldman I; Favor M; Dizon M; Litwin A; Malhotra R
    Eye (Lond); 2019 Mar; 33(3):349-352. PubMed ID: 30202071
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy of botulinum toxin A for treatment of unilateral spasms of the eyelid and its prognosis.
    Xu YP; Shen J; Zhu QB; Gu J; Lin SZ; Fan JP
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2974-9. PubMed ID: 24254570
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Botulinum neurotoxin for the treatment of movement disorders.
    Kopanidis P; Das C
    Aust J Gen Pract; 2018 Sep; 47(9):598-601. PubMed ID: 30244558
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm.
    Kenney C; Jankovic J
    J Neural Transm (Vienna); 2008; 115(4):585-91. PubMed ID: 17558461
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time.
    Drummond GT; Hinz BJ
    Can J Ophthalmol; 2001 Dec; 36(7):398-403. PubMed ID: 11794389
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment.
    Quagliato EM; Carelli EF; Viana MA
    Clin Neuropharmacol; 2010; 33(1):27-31. PubMed ID: 20124784
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Facial dystonias and rosacea: is there an association?
    Khan TT; Donaldson J; Hesse RJ
    Orbit; 2014 Aug; 33(4):276-9. PubMed ID: 24831933
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection.
    Kocabeyoglu S; Sekeroglu HT; Mocan MC; Muz E; Irkec M; Sanac AS
    Eur J Ophthalmol; 2014; 24(6):830-4. PubMed ID: 24803156
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm.
    Snir M; Weinberger D; Bourla D; Kristal-Shalit O; Dotan G; Axer-Siegel R
    Am J Ophthalmol; 2003 Jul; 136(1):99-105. PubMed ID: 12834676
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.
    Jost WH; Kohl A
    J Neurol; 2001 Apr; 248 Suppl 1():21-4. PubMed ID: 11357234
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term adherence and response to botulinum toxin in different indications.
    Lee JI; Jansen A; Samadzadeh S; Kahlen U; Moll M; Ringelstein M; Soncin G; Bigalke H; Aktas O; Moldovan AS; Waskoenig J; Jander S; Gliem M; Schnitzler A; Hartung HP; Hefter H; Albrecht P
    Ann Clin Transl Neurol; 2021 Jan; 8(1):15-28. PubMed ID: 33259153
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Blepharospasm and hemifacial spasm treated with botulinum A toxin injection].
    Wang J; Lin S; Zhang X
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1998 Oct; 33(5):291-3. PubMed ID: 11717871
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Outcomes of a regional variant of botulinum toxin type A in the treatment of essential blepharospasm and hemifacial spasms: A retrospective study.
    Maneksha V; Chakrabarty S; Tanwar M; Pillai MR
    Indian J Ophthalmol; 2021 Oct; 69(10):2777-2781. PubMed ID: 34571634
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [What to do in cases of inadequate effectiveness of botulinum toxin for the treatment of eyelid cramping?].
    Roggenkämper P
    Ophthalmologe; 2007 Sep; 104(9):763-6. PubMed ID: 17726608
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Dry eye and qualitative tear alteration in essential blepharospasm].
    Girard B; Begnaud S
    J Fr Ophtalmol; 2022 Mar; 45(3):288-297. PubMed ID: 35148903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.